Abstract: The present disclosure provides certain tri-substituted heteroaryl derivatives that are Src Homology-2 phosphatase (SHP2) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of SHP2. Also provided are pharmaceutical compositions containing such compounds and uses of such compounds.

Abstract: The use of heterocyclic inhibitors of ERK1/2 for treating cancer, specifically solid tumors. In particular, the ERK1/2 N inhibitor is (S)—N-(2-amino-1-(3-chloro-5-fluorophenyl)ethyl)-1-(5-methyl-2-((tetrahydro2H-pyran-4-yl)amino)pyrimidin-4-yl)-1H-imidazole-4-carboxamide which is administered to a subject twice a day, once a week and is used to treat cancers including non-small cell lung cancer (NSCLC), melanoma, pancreatic cancer, or colorectal cancer (CRC). In some embodiments, the cancer is a MAP-Km/MAPKi-naive pan tumor.